Rogaine Extra Strength for Men data support more hair regrowth than original formula.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE EXTRA STRENGTH "FASTER" HAIR REGROWTH CLAIM NEEDS FURTHER DATA before it can be included in proposed labeling for the baldness treatment, FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees recommended at a July 16 joint meeting in Bethesda, Md. The group agreed that, because onset of action for the 5% minoxidil solution was not a primary endpoint of sponsor Pharmacia & Upjohn's studies, the claims "Provides more hair regrowth" and "Provides regrowth sooner" are unsubstantiated and should not appear in labeling.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning